Ultra-Sensitive EGFR mutation detection kit_exon18/19/20/21

Epidermal growth factor receptor (EGFR) is one of the most frequently amplified, mutated and/or overexpressed genes in human malignancies (1). Inactivation of EGFR kinase with tyrosine kinase inhibitors (TKIs), such as gefitinib (Iressa) and erlotinib (Tarceva), suppresses signal transduction pathways which control tumor cell growth, proliferation, and resistance to apoptosis. TKIs therapy has shown a significant symptom benefit and prolongs survival on the treatment of Non-Small Cell Lung Cancer (NSCLC) patients with somatic mutations in the EGFR gene. Therefore, detection of the somatic mutations in the EGFR gene may predict a more accurate response of the cancer patients to TKIs therapy.